

Brian C Healy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/130265/publications.pdf>

Version: 2024-02-01

151
papers

6,784
citations

101543

36
h-index

76900

74
g-index

154
all docs

154
docs citations

154
times ranked

10593
citing authors

#	ARTICLE	IF	CITATIONS
1	An Adaptive, Algorithm-based Text Message Intervention to Promote Health Behavior Adherence in Type 2 Diabetes: Treatment Development and Proof-of-Concept Trial. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 364-373.	2.2	3
2	Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 74, 1275-1278.	5.8	23
3	Predictors of completion and response to a psychological intervention to promote health behavior adherence in heart failure. <i>International Journal of Psychiatry in Medicine</i> , 2022, 57, 21-34.	1.8	0
4	Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. <i>Quality of Life Research</i> , 2022, 31, 1799-1805.	3.1	6
5	Demand with low supply: A pipeline for personalized integrative medicine in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103493.	2.0	2
6	Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732110693.	1.0	3
7	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. <i>Science</i> , 2022, 375, 296-301.	12.6	892
8	Early Predictors of Clinical and <sc>MRI</sc> Outcomes Using <sc>Least Absolute Shrinkage and Selection Operator (LASSO)</sc> in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 92, 87-96.	5.3	11
9	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211049.	1.0	2
10	Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 593-602.	3.0	8
11	A positive psychology-motivational interviewing program to promote physical activity in type 2 diabetes: The BEHOLD-16 pilot randomized trial. <i>General Hospital Psychiatry</i> , 2021, 68, 65-73.	2.4	17
12	Age Differences in the Use of Health Information Technology Among Adults in the United States: An Analysis of the Health Information National Trends Survey. <i>Journal of Aging and Health</i> , 2021, 33, 147-154.	1.7	25
13	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 388-393.	2.0	8
14	Machine and deep learning in MS research are just powerful statistics â€“ No. <i>Multiple Sclerosis Journal</i> , 2021, 27, 663-664.	3.0	6
15	Gut Microbiome in Progressive Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 1195-1211.	5.3	115
16	Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199907.	1.0	4
17	Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110108.	1.0	2
18	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110155.	1.0	7

#	ARTICLE	IF	CITATIONS
19	The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110075.	1.0	5
20	A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 2276-2279.	2.4	14
21	Randomized Study of Bedside vs Hallway Rounding. <i>Neurology</i> , 2021, 97, 434-442.	1.1	8
22	Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102910.	2.0	1
23	Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 631-638.	3.7	9
24	Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103311.	2.0	2
25	Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating TÁcells. <i>IScience</i> , 2021, 24, 103347.	4.1	4
26	Developing a Psychological Behavioral Intervention in Cardiac Patients Using the Multiphase Optimization Strategy: Lessons Learned From the Field. <i>Annals of Behavioral Medicine</i> , 2020, 54, 151-163.	2.9	5
27	Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1708-1718.	3.0	25
28	Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 58.	9.0	135
29	7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. <i>Multiple Sclerosis Journal</i> , 2020, 26, 177-187.	3.0	49
30	Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 179-184.e3.	1.9	6
31	Text Message Interventions for Physical Activity: A Systematic Review and Meta-Analysis. <i>American Journal of Preventive Medicine</i> , 2020, 58, 142-151.	3.0	69
32	Return to College After a First Episode of Psychosis. <i>Schizophrenia Bulletin Open</i> , 2020, 1, sgaa041.	1.7	7
33	Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. <i>Journal of Psychosomatic Research</i> , 2020, 138, 110252.	2.6	31
34	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2333-2344.	27.0	1,102
35	Response to Letter to the Editor: Real-World Considerations for Applicability of Text Message Interventions for Promotion of Physical Activity. <i>American Journal of Preventive Medicine</i> , 2020, 59, e93-e94.	3.0	0
36	Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 30639-30648.	7.1	25

#	ARTICLE	IF	CITATIONS
37	Exploring the feasibility and impact of positive psychology-motivational interviewing interventions to promote positive affect and physical activity in type 2 diabetes: design and methods from the BEHOLD-8 and BEHOLD-16 clinical trials. <i>Health Psychology and Behavioral Medicine</i> , 2020, 8, 398-422.	1.8	5
38	MRI activity in MS and completed pregnancy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	13
39	Feasibility and preliminary efficacy of a positive psychology-based intervention to promote health behaviors in heart failure: The REACH for Health study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110285.	2.6	16
40	Diet pattern and prodromal features of Parkinson disease. <i>Neurology</i> , 2020, 95, e2095-e2108.	1.1	45
41	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	17
42	Temporal association of sNfL and gad6-enhancing lesions in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 945-955.	3.7	35
43	A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study. <i>Metabolites</i> , 2020, 10, 99.	2.9	12
44	A novel classification of fatigue in multiple sclerosis based on longitudinal assessments. <i>Multiple Sclerosis Journal</i> , 2020, 26, 725-734.	3.0	13
45	Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. <i>Journal of Neuroimaging</i> , 2020, 30, 212-218.	2.0	11
46	Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1011-1021.	2.8	5
47	Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101944.	2.0	7
48	Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2020, 2020, 1-7.	0.8	0
49	Randomized controlled trial of a well-being intervention in cardiac patients. <i>General Hospital Psychiatry</i> , 2019, 61, 116-124.	2.4	14
50	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 119-127.	2.0	30
51	A Pilot Study to Assess At-Home Speed of Processing Training for Individuals with Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-7.	0.8	1
52	History of fatigue in multiple sclerosis is associated with grey matter atrophy. <i>Scientific Reports</i> , 2019, 9, 14781.	3.3	24
53	Adipokines are associated with pediatric multiple sclerosis risk and course. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101384.	2.0	20
54	The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 403, 38-43.	0.6	14

#	ARTICLE	IF	CITATIONS
55	Is it better to cultivate positive affect or optimism? Predicting improvements in medical adherence following a positive psychology intervention in patients with acute coronary syndrome. <i>General Hospital Psychiatry</i> , 2019, 61, 125-129.	2.4	12
56	Does timeframe adjustment of the Life Orientation Test-Revised assess optimism as a state?. <i>Journal of Positive Psychology</i> , 2019, 14, 799-806.	4.0	10
57	MRI phenotypes in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e530.	6.0	28
58	Usefulness of a Positive Psychology-Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity After an Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2019, 123, 1906-1914.	1.6	43
59	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731982840.	1.0	7
60	Time between expanded disability status scale (EDSS) scores. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 98-103.	2.0	16
61	The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. <i>BMC Neurology</i> , 2019, 19, 23.	1.8	93
62	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. <i>Npj Digital Medicine</i> , 2019, 2, 123.	10.9	35
63	Food allergies are associated with increased disease activity in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 629-635.	1.9	6
64	Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1791-1799.	3.0	9
65	Study of serum microrna expression in amyotrophic lateral sclerosis patients: The challenge of selecting suitable internal control for normalization. <i>Muscle and Nerve</i> , 2019, 59, E3-E4.	2.2	1
66	State gratitude for one's life and health after an acute coronary syndrome: Prospective associations with physical activity, medical adherence and re-hospitalizations. <i>Journal of Positive Psychology</i> , 2019, 14, 283-291.	4.0	9
67	Individual differences in self-rated anxiety and respiratory sinus arrhythmia predict performance on a complex working memory task. <i>Cognition, Brain, Behavior an Interdisciplinary Journal</i> , 2019, 23, 145-255.	0.1	0
68	Correlating serum micrnas and clinical parameters in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2018, 58, 261-269.	2.2	78
69	A probiotic modulates the microbiome and immunity in multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 1147-1161.	5.3	158
70	Optimizing a Positive Psychology Intervention to Promote Health Behaviors After an Acute Coronary Syndrome: The Positive Emotions After Acute Coronary Events III (PEACE-III) Randomized Factorial Trial. <i>Psychosomatic Medicine</i> , 2018, 80, 526-534.	2.0	56
71	Investigation of probiotics in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 58-63.	3.0	112
72	Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1126-1130.	3.0	5

#	ARTICLE	IF	CITATIONS
73	Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1105-1114.	3.0	23
74	Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 273-277.	2.0	24
75	Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. <i>PLoS ONE</i> , 2018, 13, e0206939.	2.5	15
76	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1478-1491.	3.7	115
77	Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. <i>Journal of the Neurological Sciences</i> , 2018, 394, 127-131.	0.6	8
78	Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis. <i>Brain and Behavior</i> , 2018, 8, e01068.	2.2	7
79	Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. <i>ENeurologicalSci</i> , 2018, 12, 42-46.	1.3	16
80	Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2018, 392, 94-99.	0.6	14
81	Identification of MS-specific serum miRNAs in an international multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e491.	6.0	59
82	Predictors of completion of a psychological-behavioral intervention in acute coronary syndrome patients. <i>Journal of Psychosomatic Research</i> , 2018, 112, 9-12.	2.6	3
83	Joint assessment of dependent discrete disease state processes. <i>Statistical Methods in Medical Research</i> , 2017, 26, 1182-1198.	1.5	2
84	A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017, 127, 396-403.	1.6	10
85	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. <i>JAMA Neurology</i> , 2017, 74, 275.	9.0	52
86	Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. <i>Neurology</i> , 2017, 88, 677-684.	1.1	20
87	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017, 127, 971-980.	1.6	12
88	Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2017, 27, 481-485.	2.0	34
89	Associations Between Psychological Constructs and Cardiac Biomarkers After Acute Coronary Syndrome. <i>Psychosomatic Medicine</i> , 2017, 79, 318-326.	2.0	26
90	The Positive Emotions after Acute Coronary Events behavioral health intervention: Design, rationale, and preliminary feasibility of a factorial design study. <i>Clinical Trials</i> , 2017, 14, 128-139.	1.6	30

#	ARTICLE	IF	CITATIONS
91	Depression and fatigue in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017, 380, 236-241.	0.6	52
92	A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017, 383, 221-229.	0.6	20
93	Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 196-201.	2.0	13
94	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 47-53.	2.0	15
95	Exploration of machine learning techniques in predicting multiple sclerosis disease course. <i>PLoS ONE</i> , 2017, 12, e0174866.	2.5	122
96	The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2016, 7, 99.	2.4	6
97	Risk attitudes and risk perceptions in individuals with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731666540.	1.0	9
98	Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis. <i>American Journal of Ophthalmology</i> , 2016, 165, 54-64.	3.3	26
99	Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e267.	6.0	77
100	The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. <i>BMC Medical Imaging</i> , 2016, 16, 56.	2.7	14
101	Reserve and Reserve-building activities research: key challenges and future directions. <i>BMC Neuroscience</i> , 2016, 17, 62.	1.9	26
102	Does early (treatment in) BENEFIT lead to late MS benefit?. <i>Neurology</i> , 2016, 87, 970-971.	1.1	0
103	Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2016, 26, 62-67.	2.0	48
104	Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 354-361.	3.0	37
105	An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 531-538.	3.6	9
106	Relationship of optimism and suicidal ideation in three groups of patients at varying levels of suicide risk. <i>Journal of Psychiatric Research</i> , 2016, 77, 76-84.	3.1	24
107	The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2016, 26, 184-187.	2.0	12
108	Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2016, 22, 935-943.	3.0	64

#	ARTICLE	IF	CITATIONS
109	Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1841-1849.	3.0	41
110	Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness. <i>Value in Health</i> , 2016, 19, 185-191.	0.3	26
111	Clinical and MRI phenotype of children with MOG antibodies. <i>Multiple Sclerosis Journal</i> , 2016, 22, 174-184.	3.0	130
112	Domain Induced Dirichlet Mixture of Gaussian Processes: An Application to Predicting Disease Progression in Multiple Sclerosis Patients. , 2015, , .		3
113	Relationships between positive psychological constructs and health outcomes in patients with cardiovascular disease: A systematic review. <i>International Journal of Cardiology</i> , 2015, 195, 265-280.	1.7	137
114	Effect of vitamin D on MS activity by disease-modifying therapy class. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e167.	6.0	47
115	Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. <i>American Heart Journal</i> , 2015, 170, 1105-1115.	2.7	213
116	Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 598-606.	2.0	10
117	Progression rates and sample size estimates for PPMS based on the CLIMB study population. <i>Multiple Sclerosis Journal</i> , 2015, 21, 180-188.	3.0	9
118	Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients. <i>Artificial Intelligence in Medicine</i> , 2015, 65, 79-88.	6.5	9
119	Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. <i>NeuroImage</i> , 2015, 119, 81-88.	4.2	8
120	Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort. <i>JAMA Neurology</i> , 2015, 72, 152.	9.0	328
121	T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. <i>BMC Neurology</i> , 2015, 15, 124.	1.8	21
122	Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors. <i>Journal of Neuroimaging</i> , 2015, 25, 191-199.	2.0	22
123	The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. <i>Neurology</i> , 2015, 85, 1209-1213.	1.1	14
124	Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 2425-2432.	3.6	24
125	Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. <i>NeuroImage: Clinical</i> , 2015, 8, 606-610.	2.7	21
126	The Loyalty Continuum: Differentiating Between Stages of Loyalty Development. <i>Journal of Marketing Theory and Practice</i> , 2014, 22, 367-384.	4.3	15

#	ARTICLE	IF	CITATIONS
127	Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events. JAMA Internal Medicine, 2014, 174, 927.	5.1	161
128	Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology, 2014, 82, 2173-2179.	1.1	54
129	Feasibility and utility of positive psychology exercises for suicidal inpatients. General Hospital Psychiatry, 2014, 36, 88-94.	2.4	128
130	MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2014, 346, 250-254.	0.6	31
131	An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Multiple Sclerosis Journal, 2014, 20, 1381-1390.	3.0	29
132	Treatment Satisfaction in Multiple Sclerosis. International Journal of MS Care, 2014, 16, 68-75.	1.0	28
133	Altruism and health outcomes in multiple sclerosis: The effect of cognitive reserve. Journal of Positive Psychology, 2013, 8, 144-152.	4.0	13
134	Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis. Multiple Sclerosis International, 2013, 2013, 1-9.	0.8	38
135	Removing Confounding Factors via Constraint Based Clustering: An Application to Finding Homogeneous Groups of Multiple Sclerosis Patients. , 2013, , .		0
136	Effect of gender on late-onset multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1472-1479.	3.0	96
137	The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Quality of Life Research, 2012, 21, 1677-1684.	3.1	23
138	Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle and Nerve, 2012, 46, 506-511.	2.2	20
139	Approaches to Normalization of Spinal Cord Volume: Application to Multiple Sclerosis. Journal of Neuroimaging, 2012, 22, e12-9.	2.0	53
140	Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. Journal of the Neurological Sciences, 2011, 303, 109-113.	0.6	7
141	Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis. , 2011, 21, e50-e56.		98
142	Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. Journal of Neurology, 2011, 258, 1812-1819.	3.6	9
143	Optimal design and analysis of phase I/III clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. Multiple Sclerosis Journal, 2010, 16, 840-847.	3.0	11
144	A method for evaluating treatment switching criteria in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1483-1489.	3.0	19

#	ARTICLE	IF	CITATIONS
145	Smoking and Disease Progression in Multiple Sclerosis. Archives of Neurology, 2009, 66, 858-64.	4.5	182
146	Modeling disease state transition heterogeneity through Bayesian variable selection. Statistics in Medicine, 2009, 28, 1353-1368.	1.6	8
147	Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis. Journal of the Neurological Sciences, 2009, 278, 54-59.	0.6	2
148	Accommodating Uncertainty in a Tree Set for Function Estimation. Statistical Applications in Genetics and Molecular Biology, 2008, 7, Article5.	0.6	2
149	Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale. Archives of Neurology, 2008, 65, 1449.	4.5	53
150	Off-Label Use of Recombinant FVIIa: Clinical Characteristics That May Influence Outcomes.. Blood, 2005, 106, 431-431.	1.4	2
151	Text message preferences among individuals with type 2 diabetes: A brief report of an online survey study. Current Psychology, 0, , .	2.8	0